Wordt geladen...
Ten years of biosimilar recombinant human growth hormone in Europe
Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years. With the expiration of patent exclusivity for the first wave of rhGH products and other biopharmaceuticals, the opportunity emerged for the development of biosimilar medicines. A biosimilar is defined by the Eur...
Bewaard in:
| Gepubliceerd in: | Drug Des Devel Ther |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5439961/ https://ncbi.nlm.nih.gov/pubmed/28553081 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S130317 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|